CW August 2002
Volume 11Issue Number 8 August 2002 ISSN 10593802 Favorable Response Rates and Good Tolerability in Metastatic Breast CancerIn refractory metastatic breast cancer, irinotecan (Camptosar) produced response rates comparable to those reported for the FDA-approved agent capecitabine (Xeloda), but without the hand/foot syndrome common to capecitabine, and with low incidence of febrile neutropenia.
Go to Previous Page Go to Next Page Source & Additional Reading ASCO Annual Meeting, Orlando. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW August 2002Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
